Synvolux Therapeutics B.V.

Synvolux Therapeutics BV. is active drug delivery since 2002. Synvolux is based in Groningen, the Netherlands. Its mission is to develop novel, innovative products for unmet medical needs. Its proprietary technology is unique, safe and highly efficacious in delivery of macromolecular compounds.

Synvolux’ delivery technology (SAINT™) is based on a set of proprietary, entirely synthetic lipid structures which have demonstrated to be extremely safe and broadly applicable.

SAINT performance SAINT has been shown to be very effective in transporting DNA, RNA (siRNA and RNAi) and proteins to the target destination, both in vitro and in vivo. In head-to-head comparisons, SAINT has demonstrated to outperform any other delivery modality tested, both in terms of efficiency as in terms of material requirement. The SAINT delivery technology is non-toxic, and the delivered payload is biologically active and functional.

In experiments it was demonstrated that SAINT is an impressive enhancer for siRNA delivery in in vivo applications. Summarizing the SAINT advantages: - Delivery of all classes: DNA, RNA and protein - 100% gene silencing possible with siRNA - Superior in vitro and in vivo delivery - No interference from blood, serum components - Demonstrated safety: no toxicity, no apoptosis - Extremely low material requirements for payload